Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, as they receive approval to initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346.
Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals
January 6, 2019
Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding
Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346. The study will run in Canada and is expected to conclude in December 2018.
Veristat Partners with TRI For Risk-Based Monitoring Technology
November 5, 2018
Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients
Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma
Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™
August 20, 2018
Continues Collaboration to Provide Regulatory Submission Support for
Additional Patisiran Submissions
SOUTHBOROUGH, MA – August 20, 2018 – Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Veristat Congratulates Agios on the FDA Approval of TIBSOVO®
August 16, 2018
The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
SOUTHBOROUGH, MA – August 16, 2018 – Veristat, a full service Clinical Research Organization (CRO), congratulates Agios on the recent FDA approval of TIBSOVO® (ivosidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test.
Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year
August 15, 2018
Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the Company to Execute High Quality Trials That Reach Regulatory Approval
SOUTHBOROUGH, MA – August 15, 2018 – Veristat, a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States.
Veristat Recognized for a Third Consecutive Year on the Inc. 5000 List of America’s Fastest-Growing Private Companies
August 21, 2017
Veristat’s Growth Positively Impacts Our Ability to Help Clients Achieve Regulatory Approval of their Life-Changing and Life-Saving Therapies
SOUTHBOROUGH, MA – August 21, 2017 – Veristat announced today that it has been recognized for a third consecutive year by Inc. Magazine as one of America’s fastest-growing private companies. Veristat joined the list in 2015.
Veristat and AOBiome Establish a Preferred Partnership To Support Ongoing & Impending Clinical Programs
June 19, 2017
SOUTHBOROUGH, MA – June 19, 2017 – Veristat, a full service Clinical Research Organization (CRO), announced today that Veristat and AOBiome, a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions, have entered into a Preferred Provider Agreement (PPA).